Haviland Kate 4
4 · Blueprint Medicines Corp · Filed Apr 3, 2025
Insider Transaction Report
Form 4
Haviland Kate
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Sale
Common Stock
2025-04-01$85.47/sh−600$51,282→ 167,827 total - Sale
Common Stock
2025-04-01$86.14/sh−598$51,512→ 167,229 total - Sale
Common Stock
2025-04-01$87.34/sh−1,200$104,808→ 166,029 total - Sale
Common Stock
2025-04-01$88.59/sh−100$8,859→ 165,929 total
Footnotes (4)
- [F1]Effected pursuant to a trading plan adopted on August 30, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported is an average sale price. The shares were sold in multiple transactions ranging from $84.93 to $85.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is an average sale price. The shares were sold in multiple transactions ranging from $85.93 to $86.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is an average sale price. The shares were sold in multiple transactions ranging from $86.97 to $87.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.